Skip to Main Content

Paper Details

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive <i>SOD1</i> ALS.
Neurology
81
2018
Author NameAffiliation
David A SchoenfeldUniversity of Miami, Umea University, Massachusetts General Hospital (D.S.), Harvard Medical School and Department of Biostatistics (D.S.), Harvard Chan School of Public Health
  • 1 - 1

Datasets

Release 1.2